Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer

Biochemical Pharmacology

Volumn 82, Issue 9, 2011, Pages 1100-1109

  Nagaprashantha, Lokesh Dalasanur ^a   Vatsyayan, Rit ^b   Singhal, Jyotsana ^a   Fast, Spence ^b   Roby, Rhonda ^b   Awasthi, Sanjay ^a   Singhal, Sharad S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Docetaxel; Prostate cancer; Tumor xenografts; Vicenin 2

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FLAVONOID; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PROTEIN KINASE B; PROTEIN P53; PROTEIN P70S6K; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UVOMORULIN; VICENIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION PROTECTION; TUMOR REGRESSION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AORTA; APIGENIN; APOPTOSIS; CELL LINE; CELL MOVEMENT; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLUCOSIDES; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS; TISSUE CULTURE TECHNIQUES;

EID: 80053985343     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.07.078     Document Type: Article

References (50)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2008). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission.
2. M. Andreoiu, and L. Cheng Multifocal prostate cancer: biologic, prognostic, and therapeutic implications Hum Pathol 41 2010 781 793
3. S.A. Tomlins, R. Mehra, D.R. Rhodes, X. Cao, L. Wang, and S.M. Dhanasekaran Integrative molecular concept modeling of prostate cancer progression Nat Genet 39 2007 41 51 (Pubitemid 46026500)
4. M.C. Lee, A.S. Moussa, C. Yu, M.W. Kattan, C. Magi-Galluzzi, and J.S. Jones Multi-focal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer J Urol 184 2010 1958 1962
5. S.E. Delacroix, and J.F. Ward Prostate cancer multifocality: impact on cancer biology and treatment recommendations Panminerva Med 52 2010 209 216
6. C. Abate-Shen, and M.M. Shen Molecular genetics of prostate cancer Genes Dev 14 2010 2410 2434
7. K. Ellwood-Yen, T.G. Graeber, J. Wongvipat, M.L. Iruela-Arispe, J. Zhang, and R. Matusik Myc-driven murine prostate cancer shares molecular features with human prostate tumors Cancer Cell 4 2003 223 238 (Pubitemid 37163836)
8. S. Wang, J. Gao, Q. Lei, N. Rozengurt, C. Pritchard, and J. Jiao Prostate-specific deletion of the murine pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 2003 209 221 (Pubitemid 37163835)
9. A. Sharma, W.S. Yeow, A. Ertel, I. Coleman, N. Clegg, and C. Thangavel The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression J Clin Invest 120 2010 4478 4492
10. J.M. Chan, M.J. Stampfer, J. Ma, P. Gann, J.M. Gaziano, and M. Pollak Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer J Natl Cancer Inst 94 2002 1099 1106 (Pubitemid 34830730)
11. T.J. McDonnell, P. Troncoso, S.M. Brisbay, C. Logothetis, L.W. Chung, and J.T. Hsieh Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940 6944 (Pubitemid 23006303)
12. I.M. van Oort, K. Tomita, A. van Bokhoven, M.J. Bussemakers, L.A. Kiemeney, and H.F. Karthaus The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study Prostate 67 2007 1432 1438 (Pubitemid 47435789)
13. S. Singh, D.K. Majumdar, and H.M. Rehan Evaluation of anti-inflammatory potential of fixed oil of ocimum sanctum (holybasil) and its possible mechanism of action J Ethnopharmacol 54 1996 19 26 (Pubitemid 26379872)
14. V. Rai, U. Iyer, and U.V. Mani Effect of tulasi (ocimum sanctum) leaf powder supplementation on blood sugar levels, serum lipids and tissue lipids in diabetic rats Plant Foods Hum Nutr 50 1997 9 16 (Pubitemid 27237703)
15. M.A. Trush, and T.W. Kensler An overview of the relationship between oxidative stress and chemical carcinogenesis Free Radic Biol Med 10 1991 201 209 (Pubitemid 121003229)
16. A.L. Sabichi, and S.M. Lippman COX-2 inhibitors and other non-steroidal anti-inflammatory drugs in genitourinary cancer Semin Oncol 31 2004 36 44 (Pubitemid 38879413)
17. R.P. Singh, G. Sharma, S. Dhanalakshmi, C. Agarwal, and R. Agarwal Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis Cancer Epidemiol Biomarkers Prev 12 2003 933 939 (Pubitemid 37151532)
18. K. Karthikeyan, P. Ravichandran, and S. Govindasamy Chemopreventive effect of ocimum sanctum on DMBA-induced hamster buccal pouch carcinogenesis Oral Oncol 35 1999 112 119 (Pubitemid 28546853)
19. F.K. Engels, and J. Verweij Docetaxel administration schedule: from fever to tears? A review of randomised studies Eur J Cancer 41 2005 1117 1126 (Pubitemid 40725569)
20. D.P. Petrylak Future directions in the treatment of androgen-independent prostate cancer Urology 65 2005 8 12 (Pubitemid 40804366)
21. S. Oudard, M.E. Legrier, K. Boye, R. Bras-Goncalves, G. De Pinieux, and P. De Cremoux Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts J Urol 169 2003 1729 1734 (Pubitemid 36443482)
22. T.M. Beer, C.W. Ryan, P.M. Venner, D.P. Petrylak, G.S. Chatta, and J.D. Ruether Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators J Clin Oncol 25 2007 669 674 (Pubitemid 350002922)
23. J. Singhal, S.S. Singhal, S. Yadav, S. Suzuki, M.M. Warnke, and A. Yacoub RLIP76 in defense of radiation poisoning Int J Radiat Oncol Biol Phys 72 2008 553 561
24. D.S. Baskin, H. Ngo, and V.V. Didenko Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts Toxicol Sci 74 2003 361 368 (Pubitemid 36958305)
25. S.S. Singhal, S. Yadav, R. Vatsyayan, P. Chaudhary, J. Borvak, and J. Singhal Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis Cancer Lett 283 2009 152 158
26. S.S. Singhal, S. Yadav, K. Drake, J. Singhal, and S. Awasthi Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1 J Biol Chem 283 2008 19714 19729
27. N. Xiang, R. Zhao, and W. Zhong Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells Cancer Chemother Pharmacol 63 2009 351 362
28. T. Yi, Z. Yi, S.G. Cho, J. Luo, M.K. Pandey, and B.B. Aggarwal Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling Cancer Res 68 2008 1843 1850 (Pubitemid 351416570)
29. P.U. Devi, K.S. Bisht, and M. Vinitha A comparative study of radioprotection by ocimum flavonoids and synthetic aminothiol protectors in the mouse Br J Radiol 71 1998 782 784 (Pubitemid 28342465)
30. J. Fang, Q. Zhou, X.L. Shi, and B.H. Jiang Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells Carcinogenesis 28 2007 713 723 (Pubitemid 46523369)
31. E.M. Yu, M. Jain, and J.B. Aragon-Ching Angiogenesis inhibitors in prostate cancer therapy Discov Med 10 2010 521 530
32. R.A. Marks, S. Zhang, R. Montironi, R.P. McCarthy, G.T. MacLennan, and A. Lopez-Beltran Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis Prostate 68 2008 919 923 (Pubitemid 351794156)
33. N. Gao, Z. Zhang, B.H. Jiang, and X. Shi Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer Biochem Biophys Res Commun 310 2003 1124 1132 (Pubitemid 37237653)
34. B.G. Gabrielli, B. Sarcevic, J. Sinnamon, G. Walker, M. Castellano, and X.Q. Wang A cyclin D-Cdk4 activity required for G2 phase cell cycle progression is inhibited in ultraviolet radiation-induced G2 phase delay J Biol Chem 274 1999 13961 13969
35. F. Yin, A.E. Giuliano, R.E. Law, and A.J. Van Herle Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells Anticancer Res 21 2001 413 420 (Pubitemid 32267675)
36. K.J. Woo, T.J. Lee, J.H. Bae, B.C. Jang, D.K. Song, and J.W. Cho Thimerosal induces apoptosis and G2/M phase arrest in human leukemia cells Mol Carcinog 45 2006 657 666 (Pubitemid 44406636)
37. C. Festuccia, P. Muzi, D. Millimaggi, L. Biordi, G.L. Gravina, and S. Speca Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines Endocr Relat Cancer 12 2005 983 998 (Pubitemid 41815791)
38. N.M. Schmitz, A. Hirt, M. Aebi, and K. Leibundgut Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia Am J Pathol 169 2006 1074 1079 (Pubitemid 44411968)
39. A. Tyagi, C. Agarwal, and R. Agarwal Inhibition of retinoblastoma protein (rb) phosphorylation at serine sites and an increase in rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention Mol Cancer Ther 1 2002 525 532
40. K.F. Macleod, N. Sherry, G. Hannon, D. Beach, T. Tokino, and K. Kinzler p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage Genes Dev 9 1995 935 944
41. (WAF1/CIP1) promoter and interacts with Sp1/Sp3 Proc Natl Acad Sci USA 98 2001 4510 4515 (Pubitemid 32295007)
42. A.N. Makarovskiy, E. Siryaporn, D.C. Hixson, and W. Akerley Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure Cell Mol Life Sci 59 2002 1198 1211
43. H.L. Mao, Z.Q. Zhu, and C.D. Chen The androgen receptor in hormone-refractory prostate cancer Asian J Androl 11 2009 69 73
44. D. Floryk, and E. Huberman Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-kappaB activity Cancer Res 65 2005 11588 11596 (Pubitemid 41821718)
45. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara, J.A. Jones, and M.E. Taplin Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
46. T. Scholzen, and J. Gerdes The Ki-67 protein: from the known and the unknown J Cell Physiol 182 2000 311 322 (Pubitemid 30054364)
47. M.J. Wheelock, and K.R. Johnson Cadherins as modulators of cellular phenotype Annu Rev Cell Dev Biol 19 2003 207 235 (Pubitemid 37487348)
48. J. Yang, and R.A. Weinberg Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis Dev Cell 14 2008 818 829 (Pubitemid 351757205)
49. P.R. Almeida, V.A. Ferreira, C.C. Santos, F.D. Rocha-Filho, R.R. Feitosa, and E.A. Falcao E-cadherin immuno-expression patterns in the characterisation of gastric carcinoma histotypes J Clin Pathol 63 2010 635 639
50. M.M. Shen, and C. Abate-Shen Molecular genetics of prostate cancer: new prospects for old challenges Genes Dev 24 2010 1967 2000